These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32609019)

  • 1. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
    Manceur AM; Ding Z; Muser E; Obando C; Voelker J; Pilon D; Kinkead F; Lafeuille MH; Lefebvre P
    J Med Econ; 2020 Oct; 23(10):1092-1101. PubMed ID: 32609019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population.
    Pilon D; Ding Z; Muser E; Obando C; Voelker J; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P
    Curr Med Res Opin; 2020 Aug; 36(8):1285-1294. PubMed ID: 32427006
    [No Abstract]   [Full Text] [Related]  

  • 3. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study.
    Gagnon-Sanschagrin P; Sanon M; Davidson M; Willey C; Kachroo S; Hoops T; Naessens D; Guerin A; Cloutier M
    J Med Econ; 2024; 27(1):931-940. PubMed ID: 38965985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
    Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
    J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.
    Holko P; Kawalec P; Mossakowska M; Pilc A
    PLoS One; 2016; 11(12):e0168586. PubMed ID: 27992531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal burden of cluster headache in the United States: a descriptive economic analysis.
    Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
    J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
    Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 12. Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis.
    Samant S; Chen E; Carias C; Kujawski SA
    J Med Econ; 2024; 27(1):1046-1052. PubMed ID: 39092467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The direct and indirect cost burden of Crohn's disease and ulcerative colitis.
    Gibson TB; Ng E; Ozminkowski RJ; Wang S; Burton WN; Goetzel RZ; Maclean R
    J Occup Environ Med; 2008 Nov; 50(11):1261-72. PubMed ID: 19001952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
    Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
    J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of sarcoidosis in a commercially-insured population in the United States.
    Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
    J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
    Parasuraman S; Thiel E; Park J; Teschemaker A
    J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 20. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.